1 of 1
Story summary
- Eli Lilly received FDA approval for Mounjaro to reduce heart attack and stroke risk in high-risk type 2 diabetics.
- A head-to-head trial found Mounjaro cut major adverse heart events 8% more than Lilly’s Trulicity.
- Mounjaro sales jumped 91% to $9.94 billion in the second quarter as global demand surged.
- Novo Nordisk secured 2024 FDA approval for Wegovy to lower heart risk in overweight adults.
